Kiniksa Pharmaceuticals (KNSA) Set to Announce Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is set to release its earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Kiniksa Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ:KNSA opened at $27.44 on Monday. The stock has a market cap of $1.95 billion, a PE ratio of 249.45 and a beta of 0.33. The company’s fifty day moving average is $25.68 and its 200 day moving average is $22.31. Kiniksa Pharmaceuticals has a 52 week low of $14.12 and a 52 week high of $27.92.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on KNSA shares. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $33.60.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares of the company’s stock, valued at $2,955,028.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,692 shares of company stock valued at $2,950,315. 54.57% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.